Regarding recent ruling issued by PTO's Patent Trial and Appeal Board, BIO called the failure of PTO's Patent Trial and Appeal Board (PTAB) to properly assess important issues raised by said motion "disappointing." In addition to calling this ruling "cursory and erroneous," BIO said it "reinforces the immediate need for Congress and the PTO leadership to take clear and decisive action to prevent any further misuse and abuse of the Inter Partes Review process"